Inhalation Sciences
Inhalation Sciences is a focused CRO dedicated to inhalation drug development success, offering preclinical research and development services for orally inhaled and intra-nasal drug products. They address the specific challenges of respiratory therapies with proprietary approaches to de-risk clinical trials, and have developed a versatile platform including the PreciseInhale system and DissolvIt module. Their mission is to provide high-quality, cost-effective data to support inhalation drug development, with a vision to become the gold standard in early inhalation research and transition to clinical use. The company holds several key patents protecting its innovative PreciseInhale™ System, including US patents that confirm the platform's maturity and technological leadership.
Industries
Nr. of Employees
small (1-50)
Inhalation Sciences
Hälsovägen 7, SE – 141 57 Huddinge, Sweden
Patents
Products
Precision aerosol generation and dosing platform
Benchtop system that separates aerosol generation from dispensing to enable active, computer-controlled precision dosing for in vitro, ex vivo and in vivo exposure modules with low material consumption.
In vitro lung dissolution and absorption module
Module that deposits aerosols onto an artificial air–blood barrier to measure time-resolved dissolution and absorption with optical monitoring, single-use exposure cells and programmable fraction collection.
Air–liquid interface cell exposure module
Module for delivering controlled aerosol doses to cell cultures at the air–liquid interface for toxicology and mechanistic studies using multilayer bronchial models.
Isolated perfused lung (ex vivo) module
Ex vivo perfused and ventilated lung module for lung-specific pharmacokinetic experiments with automated perfusate sampling and mass-balance monitoring.
Single-animal nose-only and intratracheal exposure modules
Modules enabling individual rodent exposures via nose-only or intratracheal administration with active dosing control for preclinical inhalation studies.
Precision aerosol generation and dosing platform
Benchtop system that separates aerosol generation from dispensing to enable active, computer-controlled precision dosing for in vitro, ex vivo and in vivo exposure modules with low material consumption.
In vitro lung dissolution and absorption module
Module that deposits aerosols onto an artificial air–blood barrier to measure time-resolved dissolution and absorption with optical monitoring, single-use exposure cells and programmable fraction collection.
Air–liquid interface cell exposure module
Module for delivering controlled aerosol doses to cell cultures at the air–liquid interface for toxicology and mechanistic studies using multilayer bronchial models.
Isolated perfused lung (ex vivo) module
Ex vivo perfused and ventilated lung module for lung-specific pharmacokinetic experiments with automated perfusate sampling and mass-balance monitoring.
Single-animal nose-only and intratracheal exposure modules
Modules enabling individual rodent exposures via nose-only or intratracheal administration with active dosing control for preclinical inhalation studies.
Services
Contract research conducting respiratory disease models, efficacy endpoints, histopathology and molecular analyses for inhaled and intranasal candidates.
Formulation development including excipient selection, attribute characterization, process development, stability testing and analytical support for inhaled products.
Integrated pharmacokinetic services combining in vitro dissolution/absorption assays, isolated perfused lung ex vivo PK and in vivo systemic PK using nose-only and intratracheal exposure modules.
Execution of general toxicology, acute inhalation toxicology, safety pharmacology and reproductive toxicology under GLP and non‑GLP conditions.
Support for inhaled drug–device product development including device selection, compatibility testing, process development, scale-up and generation of required CMC data for submissions.
Quantitative measurement of aerosol metrics (MMAD, GSD), live aerosol concentration monitoring and dosimetry tailored to exposure modules.
Contract research conducting respiratory disease models, efficacy endpoints, histopathology and molecular analyses for inhaled and intranasal candidates.
Formulation development including excipient selection, attribute characterization, process development, stability testing and analytical support for inhaled products.
Integrated pharmacokinetic services combining in vitro dissolution/absorption assays, isolated perfused lung ex vivo PK and in vivo systemic PK using nose-only and intratracheal exposure modules.
Execution of general toxicology, acute inhalation toxicology, safety pharmacology and reproductive toxicology under GLP and non‑GLP conditions.
Support for inhaled drug–device product development including device selection, compatibility testing, process development, scale-up and generation of required CMC data for submissions.
Quantitative measurement of aerosol metrics (MMAD, GSD), live aerosol concentration monitoring and dosimetry tailored to exposure modules.
Expertise Areas
- Preclinical inhalation drug development and translational testing
- Aerosol generation and precision dosing for biological exposures
- In vitro lung dissolution and absorption assays
- Ex vivo lung models and lung-specific pharmacokinetics
Key Technologies
- Precision aerosol generation and active dosing
- Aerosol deagglomeration and transport methods
- Air–liquid interface (ALI) exposure systems
- In vitro lung dissolution/absorption assay with optical monitoring
News & Updates
Inhalation Sciences received US Patent Approval for its flagship technology, the PreciseInhale™ System, which protects methods of transporting an aerosol from an aerosol generator to a target lung using a specially designed aerosol holding chamber. This approval confirms the innovation and maturity of the platform, supporting its market launch.
Inhalation Sciences received US Patent Approval for its flagship technology, the PreciseInhale™ System, which protects methods of transporting an aerosol from an aerosol generator to a target lung using a specially designed aerosol holding chamber. This approval confirms the innovation and maturity of the platform, supporting its market launch.